Simcere Pharma (02096.HK) spent 3.932 million Hong Kong dollars on July 11 to repurchase 0.7 million shares.

On July 11, Gelunhui announced that Simcere Pharma (02096.HK) would repurchase 0.7 million shares for HKD 3.932 million on July 11, 2024, at a repurchase price per share of HKD 5.57-5.65.

Gelonghui FinanceJul 11 05:40 ET

Simcere Pharmaceutical Group COVID-19 Drug Gets Chinese Regulator's Marketing Approval

China's National Medical Products Administration (NMPA) approved an anti-SARS-CoV-2 drug developed by Simcere Pharmaceutical Group (HKG:2096) following a review, according to a Thursday filing on the Hong Kong bourse.

MT NewswiresJul 10 20:58 ET

Simcere Pharma (02096.HK): Innovative drug Xinnuoxin for COVID-19 has received regular approval from the National Medical Products Administration.

Simcere Pharma (02096.HK) announced on July 11th that on July 8th, 2024, the group's innovative drug Xiannoxin (Xianuo Teweipian/Lituonawei Pian combination package) approved with conditions by the National Medical Products Administration (“NMPA”) was converted to regular approval, used for treating adult patients with mild to moderate COVID-19 infection. Xiannoxin became the first oral anti-COVID-19 drug to be approved for regular approval in China.

Gelonghui FinanceJul 10 18:18 ET

Express News | Simcere Pharmaceutical - Regular Approval of Xiannuoxin Approved by National Medical Products Administration

ReutersJul 10 18:02 ET

Simcere Pharma (02096.HK) spent HKD 4.735 million to repurchase 0.86 million shares on July 10th.

On July 10th, Gelunhui reported that Simcere Pharma (02096.HK) announced that it will repurchase 860,000 shares at a cost of HKD 4.735 million on July 10, 2024, with a repurchase price range of HKD 5.46-5.53 per share.

Gelonghui FinanceJul 10 05:30 ET

Guoyuan Securities: Each overseas business model has its own advantages and disadvantages. Pharmaceutical companies should choose according to their own size.

Leveraging external resources is currently the most mainstream mode for Chinese pharmaceutical companies to expand overseas, which is suitable for companies with limited resources and in need of international experience accumulation, but it also means that the company's voice will be weakened and the relative benefits of sharing will be limited.

Zhitong FinanceJul 10 03:46 ET